Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 12:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 181 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Aspart Clear all
Completed Phase 4 Interventional Results available

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

NCT02688933
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
99
States / cities
Little Rock, Arkansas • Concord, California • Escondido, California + 80 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 23, 2026, 12:57 AM EDT
Terminated Phase 4 Interventional Results available

Carbohydrate Consumption as a Factor in Aspart Dosing

NCT01333514
View directory record Official record
Conditions
Diabetes
Interventions
aspart, aspart- Insulin
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 23, 2026, 12:57 AM EDT
Completed Phase 4 Interventional Results available

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D

NCT04538352
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Semaglutide, Insulin Degludec, Insulin aspart
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 23, 2026, 12:57 AM EDT
Terminated Not applicable Interventional

Evaluation of an ICU Hyperglycemia Protocol Using Insulin Aspart

NCT00206206
View directory record Official record
Conditions
Hyperglycemia
Interventions
Hyperglycemia Protocol Procedure
Procedure
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2006 · Synced Oct 23, 2026, 12:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Use of an Insulin Infusion Conversion Equation (IICE) to Control Blood Glucose in Hospitalized Patients

NCT00645827
View directory record Official record
Conditions
Glucose, Blood
Interventions
IICE Dosing, Healthcare Provider dosing
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Oct 23, 2026, 12:57 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes

NCT01850615
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Faster-acting insulin aspart, basal insulin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
32
States / cities
Birmingham, Alabama • Peoria, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 23, 2026, 12:57 AM EDT
Withdrawn Phase 4 Interventional

Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes

NCT02811484
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide-LAR plus Dapagliflozin placebo, Exenatide-LAR plus Dapagliflozin, Insulin Titration, Behavioral Therapy
Drug · Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 23, 2026, 12:57 AM EDT
Completed Phase 2 Interventional Results available

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

NCT01194258
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Insulin lispro, Insulin aspart, Recombinant human hyaluronidase PH20, Insulin glulisine, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Concord, California • Encino, California • Escondido, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 23, 2026, 12:57 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pATIENTS (Pts) With Type 1 and Type 2 Diabetes

NCT00228904
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
Placebo, Pulsatile IV insulin delivery (humalog, humulin, novolog)
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
20 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 23, 2026, 12:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study

NCT03143816
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Technosphere insulin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 23, 2026, 12:57 AM EDT
Completed Phase 3 Interventional

Afrezza® INHALE-1 Study in Pediatrics

NCT04974528
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Afrezza, Rapid-acting Insulin Analog, Basal Insulin
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
4 Years to 17 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
39
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 23, 2026, 12:57 AM EDT
Completed Not applicable Interventional Results available

Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling

NCT01684943
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Multiplex pharmacokinetic profiling, Continuous insulin monitoring
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 23, 2026, 12:57 AM EDT
Completed Phase 3 Interventional Results available

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes

NCT03268005
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Faster-acting insulin aspart, Insulin aspart, Insulin degludec, Metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
64
States / cities
Concord, California • Fresno, California • Fullerton, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 23, 2026, 12:57 AM EDT
Completed Phase 3 Interventional

Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

NCT00106366
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
68
States / cities
Birmingham, Alabama • Vestavia Hills, Alabama • Little Rock, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 23, 2026, 12:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise

NCT04292535
View directory record Official record
Conditions
Insulin, Exercise
Interventions
Placebo into the intranasal mucosa, 20 IU NovoLog Insulin aspart into the intranasal mucosa, 40 IU NovoLog Insulin aspart into the intranasal mucosa, 60 IU NovoLog Insulin aspart into the intranasal mucosa, 80 IU NovoLog Insulin aspart into the intranasal mucosa, 100 IU NovoLog Insulin aspart into the intranasal mucosa, 120 IU NovoLog Insulin aspart into the intranasal mucosa
Drug
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 23, 2026, 12:57 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

NCT02741687
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 23, 2026, 12:57 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes

NCT05946785
View directory record Official record
Conditions
Gestational Diabetes, Vascular Endothelial Function
Interventions
Acetylcholine, insulin aspart
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 23, 2026, 12:57 AM EDT
Terminated Phase 2Phase 3 Interventional

Effects of Pulsatile Intravenous Insulin Therapy on Metabolic Integrity in Patients With Diabetes Mellitus

NCT00539409
View directory record Official record
Conditions
Diabetes Mellitus, With Complications
Interventions
Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
21 Years to 85 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 23, 2026, 12:57 AM EDT
Completed Phase 3 Interventional Results available

Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes

NCT01045447
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
24
States / cities
Fresno, California • Waterbury, Connecticut • Boynton Beach, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 23, 2026, 12:57 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study

NCT01966978
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes
Interventions
Metformin, Detemir, Liraglutide, Insulin Aspart
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 23, 2026, 12:57 AM EDT
Completed Phase 4 Interventional Results available

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

NCT03336528
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Degludec, Glargine, Aspart
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 23, 2026, 12:57 AM EDT
Withdrawn Phase 3 Interventional

Effects of Pulsatile Intravenous Insulin Therapy on Cardiac Disease in Patients With Diabetes

NCT00539435
View directory record Official record
Conditions
Diabetes Mellitus, With Complications
Interventions
Intravenous Insulin on cardiac disease in diabetic pts
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
21 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 23, 2026, 12:57 AM EDT
Active, not recruiting Phase 2 Interventional

Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes

NCT04542148
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk, Diabetes, Gestational
Interventions
Sliding Scale Insulin, Up-Titration of Home Insulin, Continuous Insulin Infusion, Dexcom G6 Professional Continuous Glucose Monitor
Drug · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 50 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Birmingham, Alabama • Portland, Oregon • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 12:57 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes

NCT02500706
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
Faster-acting insulin aspart, insulin aspart, insulin degludec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
57
States / cities
Tucson, Arizona • Concord, California • Encino, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 23, 2026, 12:57 AM EDT